Xphyto and 3a are developing rapid screening tests for COVID-19 and other high-risk pandemic threats, including H1N1 (swine flu) and H5N1 (avian flu), with a specific focus on early…
Xphyto Therapeutics
Xphyto’s test may be ideal to catch the super-spreaders – the infectious carriers blithely attending drumming circles because they feel healthy….
“Visual confirmation of test results (probe activation) was observed in five to seven minutes,” states Xphyto….
3a-Diagnostics, a diagnostic partner for Xphyto Therapeutics (XPHY.C), confirmed the functionality of the peptide biosensors working in Xphyto’s oral dissolvable thin film (ODF) platform today. 3a has developed peptide-based…
Our early coverage of Xphyto reveals the following company trait: Xphyto says, “We’re going to do this” – and then they do it – quickly….
Vektor is now proceeding with process implementation for the manufacture of Rotigotine patches for human clinical studies….
Xphyto Therapeutics’ (XPHY.C) potential deal with German brewery Oettinger Brauerei GmbH means development, production and distribution of cannabis-infused beverages for the European Market. They take their beer seriously in…
XPHY owns a German narcotic manufacturer called Vektor Pharma, another subsidiary called Bunker that has all the licenses to study cannabis as a medicine, and it has formed multiple…
Xphyto Therapeutics (XPHY.C) announced today that they advancing its thin film CBD delivery system for epilepsy sufferers to clinical trials. In the past three months, the company’s German subsidiary,…
Xphyto Therapeutics (XPHY.C) German subsidiary Vektor Pharma TF GmbH will commence several research and development programs related to infectious disease, including thin film delivery of cannabigerol (CBG) and quercetic…